Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc., a subsidiary of Sumitomo Pharma Co., Ltd., is headquartered in the United States and operates primarily in North America. Founded in 2005, the company has established itself within the pharmaceutical industry, focusing on innovative treatments in areas such as central nervous system disorders, oncology, and infectious diseases. With a commitment to research and development, Sumitomo Pharma America offers unique products that address unmet medical needs, leveraging advanced technologies and scientific expertise. The company has achieved significant milestones, including strategic partnerships and the successful launch of several key therapies, solidifying its position in the competitive pharmaceutical landscape. Through its dedication to improving patient outcomes, Sumitomo Pharma America continues to make a notable impact in the healthcare sector.
DitchCarbon Score
How does Sumitomo Pharma America, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sumitomo Pharma America, Inc.'s score of 28 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sumitomo Pharma America, Inc.'s reported carbon emissions
Sumitomo Pharma America, Inc. currently does not have available carbon emissions data for the most recent year, nor do they have specified reduction targets or initiatives documented. Without specific emissions figures or commitments, it is challenging to assess their climate impact or sustainability efforts. However, the company is likely to be engaged in industry-standard practices aimed at reducing carbon footprints, aligning with broader corporate responsibility trends. As the climate landscape evolves, it is essential for companies like Sumitomo Pharma America to establish clear emissions reduction strategies and commitments to contribute effectively to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sumitomo Pharma America, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
